HRS Regulates Small Extracellular Vesicle PD-L1 Secretion and Is Associated with Anti-PD-1 Treatment Efficacy

PD-L1 localized to immunosuppressive small extracellular vesi-cles (sEV PD-L1) contributes to tumor progression and is associated with resistance to immune-checkpoint blockade (ICB) therapy. Here, by establishing a screening strategy with a combination of tissue microarray (TMA), IHC staining, and measurement of circulating sEV PD-L1, we found that the endosomal sorting complex required for transport (ESCRT) member protein hepato-cyte growth factor-regulated tyrosine kinase substrate (HRS) was the key regulator of circulating sEV PD-L1 in head and neck squamous cell carcinoma (HNSCC) patients. Increased HRS expression was found in tumor tissues and positively correlated with elevated circulating sEV PD-L1 in patients with HNSCC. The expression of HRS was also negatively correlated to the infiltration of CD8+ T cells. Knockdown of HRS markedly reduced PD-L1 expression in HNSCC cell-derived sEVs, and these sEVs from HRS knockdown cells showed decreased immunosuppressive effects on CD8+ T cells. Knockout of HRS inhibited tumor growth in immu-nocompetent mice together with PD-1 blockade. Moreover, a higher HRS expression was associated with a lower response rate to anti-PD-1 therapy in patients with HNSCC. In summary, our study reveals HRS, the core component of ESCRT-0, regulates sEV PD-L1 secretion, and is associated with the response to ICB therapy in patients with HNSCC, suggesting HRS is a promising target to improve cancer immunotherapy.

Automated summary

In this study, it was discovered that the core component of ESCRT-0, HRS, plays a crucial role in regulating the secretion of sEV PD-L1 and is associated with the response to ICB therapy in patients with HNSCC. Knockdown of HRS significantly reduced the expression of PD-L1 in HNSCC cell-derived sEVs and attenuated their immunosuppressive effects on CD8+ T cells. Additionally, higher HRS expression was found to be associated with a lower response rate to anti-PD-1 therapy in HNSCC patients. Overall, these findings suggest that HRS is a promising target for improving cancer immunotherapy.